...5Y Capital and Redpoint China Ventures, respectively. Source Code Capital, BAI Capital, Gaorong Capital and DCM...

...two other clinical programs: danicamtiv (MYK-491), which is in Phase II testing for dilated cardiomyopathy (DCM...

...and corporate compliance at Gritstone Oncology Inc. (NASDAQ:GRTS); Chao is co-founder and general partner of DCM...

...developing a gene therapy that uses an adeno-associated viral (AAV) serotype 9 vector to address DCM...
...in patients with mutated BCL2-associated athanogene 3 (BAG3; CAIR-1). About 35,000 of the 3 million DCM...

...to begin clinical testing of ACT-1 in 1H21 to treat genetic forms of dilated cardiomyopathy (DCM...

...NYSE:SNY) and MyoKardia are partnered to co-develop the biotech’s therapies for hypertrophic cardiomyopathy (HCM) and DCM...
...Status: Phase Ia data Milestone: Phase Ib data (4Q18); Phase IIa data (2019) Brian Moy MYK-491, SAR440181, dcm-1 MyoKardia...

...partnered to co-develop two MyoKardia programs for HCM, including mavacamten, and another for dilated cardiomyopathy (DCM...

...partnered to co-develop 2 MyoKardia programs for HCM, including mavacamten, and another for dilated cardiomyopathy (DCM...

...partnered to co-develop two MyoKardia programs for HCM, including mavacamten, and another for dilated cardiomyopathy (DCM). Jaime...

...which completed a Phase IIb trial to treat heart failure due to ischemic dilated cardiomyopathy (DCM...